ZyVersa Therapeutics, Inc.
ZVSA
$0.20
$0.014.17%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -22.10% | -16.69% | -19.58% | -30.64% | -34.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.09% | -21.26% | -24.51% | -33.19% | -36.64% |
| Operating Income | 25.09% | 21.26% | 24.51% | 33.19% | 36.64% |
| Income Before Tax | -174.32% | -21.14% | 63.00% | 91.66% | 91.27% |
| Income Tax Expenses | -12,811.94% | -45.75% | 99.49% | 100.08% | 100.07% |
| Earnings from Continuing Operations | -165.07% | -20.47% | 62.02% | 90.94% | 90.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -165.07% | -20.47% | 62.02% | 90.94% | 90.42% |
| EBIT | 25.09% | 21.26% | 24.51% | 33.19% | 36.64% |
| EBITDA | 25.11% | 21.24% | 24.48% | 33.18% | 36.64% |
| EPS Basic | 65.16% | 93.84% | 95.68% | 99.60% | 99.43% |
| Normalized Basic EPS | 85.85% | 88.34% | 90.57% | 95.01% | 96.52% |
| EPS Diluted | 65.16% | 93.84% | 95.68% | 99.60% | 99.43% |
| Normalized Diluted EPS | 85.85% | 88.34% | 90.57% | 95.01% | 96.52% |
| Average Basic Shares Outstanding | 436.36% | 563.20% | 515.62% | 601.41% | 1,040.05% |
| Average Diluted Shares Outstanding | 436.36% | 563.20% | 515.62% | 601.41% | 1,040.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |